Prediction of Meningioma Grade Using Hematological Parameters

Area of Science:

• Neuro-oncology
• Inflammation markers
• Tumor biology

Background:

• Predicting meningioma aggressiveness is crucial for surgical timing and strategy.
• Robust prognostic markers for meningiomas are limited.
• The systemic immune-inflammation (SII) index is a novel biomarker showing prognostic value in various cancers.

Purpose of the Study:

• To evaluate the prognostic value of the SII index, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) in intracranial meningiomas.
• To determine if these inflammatory markers correlate with tumor grade and proliferation.
• To explore their potential role in guiding treatment decisions for meningioma patients.

Main Methods:

• Retrospective review of demographic, clinical, and laboratory data from 234 patients operated on for intracranial meningioma (2017-2023).
• Analysis of SII index, NLR, and PLR values at presentation.
• Correlation analysis with tumor grade and Ki-67 index.

Main Results:

• Patients with grade ≥2 meningiomas had significantly higher SII, NLR, and PLR values.
• Positive correlations were found between SII, NLR, PLR, and the Ki-67 index (P<0.001 for SII and NLR; P<0.01 for PLR).
• Optimal cutoff values for SII (>618), NLR (>3.53), and PLR (>121.2) demonstrated significant predictive value.

Conclusions:

• This study is the first to assess the prognostic value of the SII index in intracranial meningiomas.
• Elevated SII, NLR, and PLR are associated with higher tumor grade and Ki-67 index in meningiomas.
• These inflammatory markers may help identify patients requiring aggressive treatment or closer follow-up.